ATE289311T1 - Kondensierte purinderivate - Google Patents

Kondensierte purinderivate

Info

Publication number
ATE289311T1
ATE289311T1 AT00985847T AT00985847T ATE289311T1 AT E289311 T1 ATE289311 T1 AT E289311T1 AT 00985847 T AT00985847 T AT 00985847T AT 00985847 T AT00985847 T AT 00985847T AT E289311 T1 ATE289311 T1 AT E289311T1
Authority
AT
Austria
Prior art keywords
substituted
group
unsubstituted
lower alkyl
alkyl group
Prior art date
Application number
AT00985847T
Other languages
English (en)
Inventor
Kimihisa Ueno
Akira Ogawa
Yoshihisa Ohta
Yuji Nomoto
Kotaro Takasaki
Hideaki Kusaka
Hiroshi Yano
Chiharu Suzuki
Satoshi Nakanishi
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE289311T1 publication Critical patent/ATE289311T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00985847T 1999-12-24 2000-12-22 Kondensierte purinderivate ATE289311T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP36631399 1999-12-24
PCT/JP2000/009160 WO2001047931A1 (fr) 1999-12-24 2000-12-22 Derives de purine fondue

Publications (1)

Publication Number Publication Date
ATE289311T1 true ATE289311T1 (de) 2005-03-15

Family

ID=18486475

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00985847T ATE289311T1 (de) 1999-12-24 2000-12-22 Kondensierte purinderivate

Country Status (8)

Country Link
US (1) US7005430B2 (de)
EP (1) EP1251130B1 (de)
AT (1) ATE289311T1 (de)
AU (1) AU2223501A (de)
CA (1) CA2395414A1 (de)
DE (1) DE60018216T2 (de)
ES (1) ES2238335T3 (de)
WO (1) WO2001047931A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810037B1 (fr) * 2000-06-09 2004-04-23 Aventis Pharma Sa Utilisation de derives de 2-aminothiazoline comme inhibiteurs de no-synthase inductible
US6451821B1 (en) 2000-06-09 2002-09-17 Aventis Pharma S.A. Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
UA75625C2 (en) * 2000-12-01 2006-05-15 Biogen Inc Condensed purine derivatives as a1 adenosine receptor antagonists
AU2003231538A1 (en) * 2002-05-17 2003-12-02 Kyowa Hakko Kogyo Co., Ltd. Method of searching substane having antidiabetic activity
WO2003097064A1 (fr) * 2002-05-17 2003-11-27 Kyowa Hakko Kogyo Co., Ltd. Agent de traitement du diabète
EP1533312A4 (de) * 2002-06-25 2006-05-31 Kyowa Hakko Kogyo Kk Heterobicyclische verbindungen
JPWO2004011469A1 (ja) * 2002-07-26 2005-11-24 協和醗酵工業株式会社 細胞分化誘導剤
JP4206382B2 (ja) 2002-11-19 2009-01-07 アキリオン ファーマシューティカルズ，インコーポレーテッド 置換されたアリールチオウレアおよび関連化合物；ウイルス複製のインヒビター
JP2004224756A (ja) * 2003-01-24 2004-08-12 Sumika Fine Chemicals Co Ltd ２，６−ジハロゲノ−８−置換−プリン化合物およびその製造方法
EP1604665B1 (de) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase-hemmer
US20060252780A1 (en) * 2003-04-25 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. Fused pyrimidine derivatives
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
MXPA06007242A (es) 2003-12-23 2006-08-18 Pfizer Nuevos derivados de quinolina.
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (de) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Testverfahren für die wirkung eines vaskularisierungsinhibitors
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
JPWO2007052849A1 (ja) 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
KR20080094729A (ko) * 2006-02-15 2008-10-23 아보트 러보러터리즈 강력한 ｐａｒｐ 억제제인 피라졸로퀴놀론
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
ES2355325T3 (es) * 2006-06-23 2011-03-24 Incyte Corporation Derivados de purinona como agonistas de hm74a.
KR20090025262A (ko) * 2006-06-23 2009-03-10 인사이트 코포레이션 Ｈｍ７４ａ 아고니스트로서 푸리논 유도체
EP2044074A2 (de) 2006-06-23 2009-04-08 Incyte Corporation Purinonderivate als hm74a-agonisten
RS52307B (en) * 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited CONDENSED CYCLIC UNITS
EP2044939A1 (de) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutisches mittel gegen leberfibrose
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CA2713930A1 (en) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
WO2012038980A2 (en) * 2010-09-24 2012-03-29 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2714937B1 (de) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US527316A (en) * 1894-10-09 Millie v
US4338319A (en) 1979-11-27 1982-07-06 Aktiebolaget Draco Method for the treatment of chronic obstructive airway or cardiac diseases
GB8618931D0 (en) 1986-08-02 1986-09-10 Euro Celtique Sa 6-thioxanthines
DE8900883U1 (de) 1989-01-26 1989-03-16 INDAG Gesellschaft für Industriebedarf mbH, 6900 Heidelberg Standbeutel
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
ZA902282B (en) 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor compounds
US5086176A (en) 1989-03-29 1992-02-04 Merrell Dow Pharmaceuticals Inc. Tricyclic fused adenine derivatives
US5064947A (en) 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
ATE195739T1 (de) 1989-10-20 2000-09-15 Kyowa Hakko Kogyo Kk Kondensierte purinderivate
TW252044B (de) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
WO1998015555A1 (fr) 1996-10-07 1998-04-16 Kyowa Hakko Kogyo Co., Ltd. Derives de purine fondue
JP4354016B2 (ja) * 1996-11-29 2009-10-28 株式会社メディサイエンスプラニング 新規プリン誘導体およびこれを含む医薬組成物
WO1998057651A1 (en) * 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
ATE358484T1 (de) 1998-07-02 2007-04-15 Kyowa Hakko Kogyo Kk Antidiabetische medikamente
UA75625C2 (en) * 2000-12-01 2006-05-15 Biogen Inc Condensed purine derivatives as a1 adenosine receptor antagonists

Also Published As

Publication number Publication date
US20030176698A1 (en) 2003-09-18
WO2001047931A1 (fr) 2001-07-05
DE60018216T2 (de) 2006-02-16
EP1251130B1 (de) 2005-02-16
CA2395414A1 (en) 2001-07-05
US7005430B2 (en) 2006-02-28
EP1251130A1 (de) 2002-10-23
AU2223501A (en) 2001-07-09
DE60018216D1 (de) 2005-03-24
ES2238335T3 (es) 2005-09-01
EP1251130A4 (de) 2003-05-02

Similar Documents

Publication Publication Date Title
ATE289311T1 (de) Kondensierte purinderivate
PT976748E (pt) Derivados de pirrolidina com actividade inibidora de fosfolipase a2
CY1117132T1 (el) Παραγωγο θειαζολιου
ATE404561T1 (de) Neue adeninderivate
HK1107814A1 (en) Thiadiazoline derivatives for treating cancer
HK1158637A1 (en) Mitotic kinesin inhibitor m
ATE278661T1 (de) Anthranilsäurederivate
PT916651E (pt) DERIVADOS DE áCIDO FENILALQUILCARBOXILICO
EP0371805A3 (de) Piperidin-Derivate und diese enthaltende Hypotensiva
ATE240949T1 (de) Epoxysuccinamid-derivate oder ihre salze
DE60016384D1 (de) Chondrogonese promotoren und indolin-2-on derivate
DE69930383D1 (de) Naphthimidobenzamid-derivate
DK1433480T3 (da) Lægemiddel indeholdende pyrimidin-derivat
ES2149180T3 (es) Derivado de pirazolotiazolopirimidina.
DK0998464T3 (da) Polyhydroxyalkylpyrazinderivater, deres fremstilling samt medikamenter indeholdende disse forbindelser
EP1325913A3 (de) Piperidincarbonsäuramid-Derivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties